ECSP12012011A - Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo - Google Patents

Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo

Info

Publication number
ECSP12012011A
ECSP12012011A EC2012012011A ECSP12012011A ECSP12012011A EC SP12012011 A ECSP12012011 A EC SP12012011A EC 2012012011 A EC2012012011 A EC 2012012011A EC SP12012011 A ECSP12012011 A EC SP12012011A EC SP12012011 A ECSP12012011 A EC SP12012011A
Authority
EC
Ecuador
Prior art keywords
compositions
certain
triazolopiridins
triazolopirazins
employment methods
Prior art date
Application number
EC2012012011A
Other languages
English (en)
Inventor
Wei Guo Su
Guangxiu Dai
Hong Jia
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44226181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012011(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of ECSP12012011A publication Critical patent/ECSP12012011A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se proporcionan ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo.
EC2012012011A 2009-12-31 2012-06-29 Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo ECSP12012011A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009076321 2009-12-31

Publications (1)

Publication Number Publication Date
ECSP12012011A true ECSP12012011A (es) 2012-10-30

Family

ID=44226181

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2012012011A ECSP12012011A (es) 2009-12-31 2012-06-29 Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo

Country Status (38)

Country Link
US (9) US8987269B2 (es)
EP (5) EP2519524A4 (es)
JP (5) JP5337313B2 (es)
KR (3) KR101434766B1 (es)
CN (3) CN102906092B (es)
AU (2) AU2010338712B2 (es)
BR (1) BR112012016129B1 (es)
CA (1) CA2785749C (es)
CL (1) CL2012001752A1 (es)
CO (1) CO6612235A2 (es)
CU (1) CU24167B1 (es)
CY (2) CY1118250T1 (es)
DK (3) DK3511330T3 (es)
DO (1) DOP2012000188A (es)
EA (2) EA025466B1 (es)
EC (1) ECSP12012011A (es)
ES (4) ES2546635T3 (es)
GT (1) GT201200220A (es)
HR (3) HRP20221090T1 (es)
HU (3) HUE059696T2 (es)
IL (2) IL220433B (es)
LT (1) LT3795573T (es)
ME (1) ME02211B (es)
MX (2) MX336996B (es)
MY (1) MY179933A (es)
NI (1) NI201200118A (es)
NZ (1) NZ601128A (es)
PE (3) PE20130375A1 (es)
PH (1) PH12012501355A1 (es)
PL (3) PL2719699T3 (es)
PT (3) PT2719699E (es)
RS (3) RS61281B1 (es)
SG (1) SG181781A1 (es)
SI (2) SI3511330T1 (es)
SM (3) SMT202200371T1 (es)
UA (1) UA107822C2 (es)
WO (1) WO2011079804A1 (es)
ZA (1) ZA201205730B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24167B1 (es) * 2009-12-31 2016-03-31 Hutchison Medipharma Ltd Derivados de triazolopirazinas sustituidas como inhibidores del receptor c-met o hgf para tratar el cáncer
EA025281B9 (ru) * 2010-05-17 2017-08-31 Инкозен Терапьютикс Пвт. Лтд. СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
CN103030654A (zh) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 一种小分子c-Met蛋白激酶抑制剂
CN102516046A (zh) * 2011-11-22 2012-06-27 太仓市运通化工厂 一种2-溴丙醛的合成方法
CN104321322A (zh) * 2012-03-30 2015-01-28 理森制药股份公司 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
CA2776178A1 (en) * 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
KR101745741B1 (ko) 2012-08-13 2017-06-12 한국화학연구원 신규한 트리아졸로 피라진 유도체 및 그의 용도
JP6114313B2 (ja) * 2013-01-11 2017-05-24 富士フイルム株式会社 含窒素複素環化合物またはその塩
CA2901269C (en) 2013-03-06 2022-01-18 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
CN103265468A (zh) * 2013-06-17 2013-08-28 连云港盛和生物科技有限公司 一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
AU2013402175B2 (en) * 2013-09-30 2017-09-07 Handok Inc. Novel triazolopyrazine derivative and use thereof
EP3087070B1 (en) * 2013-12-26 2017-11-08 Ignyta, Inc. Pyrazolo[1,5-a]pyridine derivatives and methods of their use
JP2016048495A (ja) * 2014-08-28 2016-04-07 京セラ株式会社 携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
CN109369656B (zh) * 2015-12-31 2021-05-07 上海医药集团股份有限公司 喹啉类化合物硫酸盐的晶型、制备方法、组合物与应用
GB201616116D0 (en) 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
KR20180092096A (ko) 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
WO2018160892A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3589628B1 (en) 2017-03-01 2025-05-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
KR101924801B1 (ko) 2017-08-16 2018-12-04 한국원자력의학원 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
BR112021004263A2 (pt) 2018-09-06 2021-05-25 Achillion Pharmaceuticals, Inc. formas mórficas de danicopano
EA202190643A1 (ru) 2018-09-11 2021-07-09 Астразенека Аб УЛУЧШЕННЫЙ СПОСОБ ПРОИЗВОДСТВА 3-[(1S)-1-ИМИДАЗО[1,2-a]ПИРИДИН-6-ИЛЭТИЛ]-5-(1-МЕТИЛПИРАЗОЛ-4-ИЛ)ТРИАЗОЛО[4,5-b]ПИРАЗИНА И ЕГО ПОЛИМОРФНЫХ ФОРМ
MX2021003425A (es) 2018-09-25 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
CR20210281A (es) * 2018-10-30 2021-10-25 Repare Therapeutics Inc Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr
MX2021006982A (es) 2018-12-14 2021-09-10 Beta Pharma Inc Compuestos sustituidos con organofosforo como inhibidores de c met, y usos terapeuticos de los mismos.
JP7471300B2 (ja) 2018-12-17 2024-04-19 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体介在性疾患を治療するための的を絞った投与
EP3941462A4 (en) 2019-03-22 2023-04-05 Achillion Pharmaceuticals, Inc. PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT-MEDIED DISEASES
CR20220068A (es) * 2019-07-22 2022-06-30 Repare Therapeutics Inc Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr
WO2021168320A1 (en) * 2020-02-20 2021-08-26 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
WO2021229605A1 (en) * 2020-05-14 2021-11-18 Dr. Reddy's Laboratories Limited Process for preparation of savolitinib and its intermediates
JP2023543990A (ja) * 2020-09-28 2023-10-19 コデクシス， インコーポレイテッド キラルアミンを合成するための操作された生体触媒および方法
US20240076285A1 (en) * 2020-12-16 2024-03-07 Shankar Venkatraman Compounds and compositions for treating conditions associated with sting activity
KR102659095B1 (ko) 2021-01-08 2024-04-19 에이비온 주식회사 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법
CN113278019A (zh) * 2021-05-31 2021-08-20 河南偶联生物科技有限公司 一种咪唑并[1,2-a]吡啶类化合物的合成方法
UY39832A (es) 2021-06-28 2023-01-31 Blueprint Medicines Corp Inhibidores de cdk2
CA3248309A1 (en) * 2022-04-20 2023-10-26 Engrail Therapeutics, Inc. γ-AMINOBUTYRIC ACID RECEPTOR MODULATOR SALTS, PARTICLES AND THEIR USES
KR20250044679A (ko) 2022-07-08 2025-04-01 아스트라제네카 아베 암 치료를 위한 hgf-수용체 억제제와 병용의 상피 성장 인자 수용체 티로신 키나아제 억제제
EP4561564A2 (en) * 2022-07-29 2025-06-04 Baylor College of Medicine Neurotrophic receptor tyrosine kinase (ntrk) inhibitors and methods using same
CN115611802B (zh) * 2022-12-02 2023-03-14 北京迪泰医药科技有限公司 一种3-乙酰基-2-氯吡啶的合成方法
EP4646411A1 (en) * 2023-01-04 2025-11-12 Blueprint Medicines Corporation Cdk2 inhibitors
GB202300923D0 (en) 2023-01-20 2023-03-08 Macfarlan Smith Ltd Novel polymorphic forms of savolitinib
WO2024263860A1 (en) * 2023-06-22 2024-12-26 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2002516326A (ja) * 1998-05-26 2002-06-04 メルク エンド カムパニー インコーポレーテッド イミダゾピリジン系トロンビン阻害薬
JP2000119250A (ja) * 1998-08-11 2000-04-25 Takeda Chem Ind Ltd 環状アミド化合物、その製造法、中間体及び除草剤
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
MXPA06000091A (es) * 2003-07-02 2006-04-07 Sugen Inc Arilmetiltriazolo e imidazopirazinas como inhibidores de c-met.
JP2007504243A (ja) 2003-09-03 2007-03-01 ニューロジェン・コーポレーション ５−アリール−ピラゾロ［４，３−ｄ］ピリミジン類、ピリジン類、ピラジン類及び関連化合物
AU2005269386A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
MX2007002050A (es) 2004-08-18 2007-03-29 Pharmacia & Upjohn Co Llc Compuestos de triazolopiridina.
CN101119996A (zh) * 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
BRPI0608160A2 (pt) * 2005-02-16 2010-11-09 Astrazeneca Ab anticorpo isolado, célula hospedeira, método de inibir o crescimento de células psma+, e, uso de um anticorpo anti-psma defucosilado
CA2630884A1 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
MY159523A (en) * 2005-12-21 2017-01-13 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
EP2032578A2 (en) 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
US8481538B2 (en) 2006-09-18 2013-07-09 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of c-Met and uses thereof
AU2007309149C1 (en) 2006-10-23 2013-04-04 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
PL2081937T3 (pl) * 2006-10-23 2013-01-31 Sgx Pharmaceuticals Inc Triazolopirydazynowe modulatory kinaz białkowych
SI3034075T1 (sl) 2006-11-22 2018-12-31 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
JP4785881B2 (ja) * 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
MX2009010984A (es) 2007-04-10 2010-01-15 Sgx Pharmaceuticals Inc Moduladores de heterociclo cinasa de anillo fusionado.
WO2008138842A1 (en) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
CA2716514A1 (en) * 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Hiv protease inhibitor and cytochrome p450 inhibitor combinations
AR070487A1 (es) 2008-02-28 2010-04-07 Novartis Ag Derivados de 3- metil- imidazo -( 1,2-b)- piridazina
ATE540038T1 (de) 2008-05-22 2012-01-15 Amgen Inc Heterocyclen als proteinkinaseinhibitoren
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
WO2011018454A1 (en) * 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
MX2012002179A (es) * 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
CU24167B1 (es) 2009-12-31 2016-03-31 Hutchison Medipharma Ltd Derivados de triazolopirazinas sustituidas como inhibidores del receptor c-met o hgf para tratar el cáncer
EA025281B9 (ru) 2010-05-17 2017-08-31 Инкозен Терапьютикс Пвт. Лтд. СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ

Also Published As

Publication number Publication date
KR20120125261A (ko) 2012-11-14
KR20140059307A (ko) 2014-05-15
HUE059696T2 (hu) 2022-12-28
JP6486999B2 (ja) 2019-03-20
CY1123777T1 (el) 2022-03-24
EP2719699A1 (en) 2014-04-16
ES2726152T3 (es) 2019-10-02
US8507487B2 (en) 2013-08-13
US20250099462A1 (en) 2025-03-27
EP3795573A1 (en) 2021-03-24
CA2785749A1 (en) 2011-07-07
SI3511330T1 (sl) 2021-01-29
DK3795573T3 (da) 2022-09-19
CN102906092A (zh) 2013-01-30
HUE025504T2 (en) 2016-02-29
US9956218B2 (en) 2018-05-01
PL2719699T3 (pl) 2016-01-29
DK2719699T3 (en) 2015-08-24
EP2966075B1 (en) 2019-02-27
CA2785749C (en) 2017-11-28
ME02211B (me) 2016-02-20
JP2013209418A (ja) 2013-10-10
PT2719699E (pt) 2015-09-30
EA030141B1 (ru) 2018-06-29
EP3511330A1 (en) 2019-07-17
IL220433B (en) 2018-01-31
HK1194071A1 (en) 2014-10-10
EA025466B1 (ru) 2016-12-30
PE20160588A1 (es) 2016-07-09
NZ601128A (en) 2014-12-24
SMT201500213B (it) 2015-10-30
AU2010338712A1 (en) 2012-07-12
US20240139182A1 (en) 2024-05-02
CN106432225A (zh) 2017-02-22
CN102906092B (zh) 2016-08-03
MX386852B (es) 2025-03-19
MX2012007756A (es) 2012-11-06
ES2927146T3 (es) 2022-11-02
CY1118250T1 (el) 2017-06-28
US20200179377A1 (en) 2020-06-11
CN106117248B (zh) 2019-01-22
IL239997A0 (en) 2015-08-31
EP3511330B1 (en) 2020-09-30
JP2018009004A (ja) 2018-01-18
JP2016155848A (ja) 2016-09-01
PH12012501355A1 (en) 2012-12-17
MX336996B (es) 2016-02-09
US11896592B2 (en) 2024-02-13
CU24167B1 (es) 2016-03-31
KR101905350B1 (ko) 2018-11-30
SG181781A1 (en) 2012-07-30
WO2011079804A1 (en) 2011-07-07
AU2015203480B2 (en) 2017-10-26
US20120264739A1 (en) 2012-10-18
AU2015203480A1 (en) 2015-07-16
NI201200118A (es) 2013-01-24
PE20211094A1 (es) 2021-06-14
JP2013516393A (ja) 2013-05-13
EA201200951A1 (ru) 2013-09-30
EP2519524A4 (en) 2013-07-03
CU20120101A7 (es) 2012-10-15
US10946014B2 (en) 2021-03-16
HK1216880A1 (en) 2016-12-09
JP2019108345A (ja) 2019-07-04
US20120245178A1 (en) 2012-09-27
CN106432225B (zh) 2019-02-19
US10512645B2 (en) 2019-12-24
JP5337313B2 (ja) 2013-11-06
ES2546635T3 (es) 2015-09-25
EA201691461A1 (ru) 2017-01-30
US20210154192A1 (en) 2021-05-27
DOP2012000188A (es) 2012-12-31
ES2840454T3 (es) 2021-07-06
HUE052828T2 (hu) 2021-05-28
EP2966075A1 (en) 2016-01-13
SMT202000693T1 (it) 2021-01-05
ZA201205730B (en) 2016-01-27
RS61281B1 (sr) 2021-02-26
SMT202200371T1 (it) 2022-11-18
KR101434766B1 (ko) 2014-08-26
US20170027934A1 (en) 2017-02-02
LT3795573T (lt) 2022-11-10
CO6612235A2 (es) 2013-02-01
US20150368271A1 (en) 2015-12-24
KR101771299B1 (ko) 2017-08-24
DK3511330T3 (da) 2020-12-21
CL2012001752A1 (es) 2013-01-25
RS54217B1 (sr) 2015-12-31
PT3511330T (pt) 2020-12-24
UA107822C2 (xx) 2015-02-25
CN106117248A (zh) 2016-11-16
MY179933A (en) 2020-11-19
PL3795573T3 (pl) 2022-11-21
HRP20221090T1 (hr) 2022-11-25
EP3795573B1 (en) 2022-07-06
AU2010338712B2 (en) 2015-04-02
BR112012016129B1 (pt) 2020-11-03
HRP20202017T1 (hr) 2021-02-19
JP6647434B2 (ja) 2020-02-14
PE20130375A1 (es) 2013-04-10
JP6194046B2 (ja) 2017-09-06
PT3795573T (pt) 2022-09-15
IL239997A (en) 2017-11-30
EP2719699B1 (en) 2015-07-08
BR112012016129A2 (pt) 2016-05-31
RS63612B1 (sr) 2022-10-31
EP2519524A1 (en) 2012-11-07
SI2719699T1 (sl) 2015-12-31
HRP20150952T1 (hr) 2015-10-09
US8987269B2 (en) 2015-03-24
KR20170098324A (ko) 2017-08-29
PL3511330T3 (pl) 2021-04-19
US20180263977A1 (en) 2018-09-20
GT201200220A (es) 2014-12-22

Similar Documents

Publication Publication Date Title
ECSP12012011A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
CR20120362A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
UY34342A (es) ?derivados de pirrolopirimidina y purina?.
CR20120158A (es) Compuestos de diòxido de iminotiadiazina como inhibidores de bace, composiciones y su uso.
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
NI201200023A (es) Derivados de 5-fluoropirimidinona
CO6680644A2 (es) Polipétidos de ralaxina modificados y sus usos
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
UY34472A (es) Derivados modificados de 4-fenil-piridina
ECSP13012877A (es) FORMAS SÓLIDAS SDE 3- (5-AMINO-2-metil -4- oxo-4H-QUINAZOL1N-3-IL) - PIPERIDIN-2, 6-DIONA, Y SUS COMPOSICIONES FARMACÉUTICAS Y USOS
EP2526112A4 (en) TARGET GENOMODIFICATION
UY34824A (es) Nucleósidos de espirooxetano de uracilo
UY34817A (es) Tienopirimidinas
UY34167A (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
PH12013500500A1 (en) Fused heteroaryls and their uses
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
ECSP12011653A (es) Derivados de n1-acil-5-fluoropirimidinona
HN2012000261A (es) Derivados de 5-fluoro-2-oxopirimidina-1(2h)-carboxilato
CL2009001973S1 (es) Mostrador.
CO6561812A2 (es) Derivados de 2-aldoximino-5-fluoropirimidina
PA8849101A1 (es) Procedimiento de preparación del hemifumarato de eplivanserina
CL2011000970S1 (es) Cepillo de dientes.